Additionally, mutations in the KRAS, BRAF, and PIK3CA genes have emerged as an important predictive marker of resistance to epidermal growth factor receptor (EGFR)-targeting monoclonal antibodies or tyrosine kinase inhibitors in colorectal and lung cancers [10]. The gene discussed is BRAF; the disease is lung carcinoma.